Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors
View ORCID ProfileAdam C. Palmer, View ORCID ProfileBenjamin Izar, View ORCID ProfilePeter K. Sorger
doi: https://doi.org/10.1101/2020.01.31.20019604
Adam C. Palmer
1Department of Pharmacology, Computational Medicine Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA
Benjamin Izar
2Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA
3Columbia University Medical Center, Columbia Center for Translational Tumor Immunology, New York, NY, USA
Peter K. Sorger
2Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA
Article usage
Posted February 04, 2020.
Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors
Adam C. Palmer, Benjamin Izar, Peter K. Sorger
medRxiv 2020.01.31.20019604; doi: https://doi.org/10.1101/2020.01.31.20019604
Subject Area
Subject Areas
- Addiction Medicine (317)
- Allergy and Immunology (621)
- Anesthesia (162)
- Cardiovascular Medicine (2300)
- Dermatology (205)
- Emergency Medicine (372)
- Epidemiology (11633)
- Forensic Medicine (10)
- Gastroenterology (685)
- Genetic and Genomic Medicine (3638)
- Geriatric Medicine (342)
- Health Economics (624)
- Health Informatics (2335)
- Health Policy (921)
- Hematology (336)
- HIV/AIDS (761)
- Medical Education (361)
- Medical Ethics (101)
- Nephrology (394)
- Neurology (3393)
- Nursing (193)
- Nutrition (512)
- Oncology (1783)
- Ophthalmology (527)
- Orthopedics (211)
- Otolaryngology (284)
- Pain Medicine (226)
- Palliative Medicine (66)
- Pathology (441)
- Pediatrics (1014)
- Primary Care Research (411)
- Public and Global Health (6031)
- Radiology and Imaging (1238)
- Respiratory Medicine (814)
- Rheumatology (370)
- Sports Medicine (319)
- Surgery (390)
- Toxicology (50)
- Transplantation (171)
- Urology (144)